229 related articles for article (PubMed ID: 11839578)
1. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability.
Kleer CG; van Golen KL; Zhang Y; Wu ZF; Rubin MA; Merajver SD
Am J Pathol; 2002 Feb; 160(2):579-84. PubMed ID: 11839578
[TBL] [Abstract][Full Text] [Related]
2. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.
Kleer CG; Griffith KA; Sabel MS; Gallagher G; van Golen KL; Wu ZF; Merajver SD
Breast Cancer Res Treat; 2005 Sep; 93(2):101-10. PubMed ID: 16187229
[TBL] [Abstract][Full Text] [Related]
3. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
[TBL] [Abstract][Full Text] [Related]
4. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
5. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.
van Golen KL; Wu ZF; Qiao XT; Bao LW; Merajver SD
Cancer Res; 2000 Oct; 60(20):5832-8. PubMed ID: 11059780
[TBL] [Abstract][Full Text] [Related]
6. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
7. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
8. Microcysts and breast cancer: a study of biological markers in archival biopsy material.
Tran DD; Lawson JS
Breast Cancer Res Treat; 2002 Oct; 75(3):213-20. PubMed ID: 12353810
[TBL] [Abstract][Full Text] [Related]
9. Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues.
Ohuchi N; Thor A; Page DL; Hand PH; Halter SA; Schlom J
Cancer Res; 1986 May; 46(5):2511-9. PubMed ID: 3084069
[TBL] [Abstract][Full Text] [Related]
10. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
11. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
Lengyel E; Prechtel D; Resau JH; Gauger K; Welk A; Lindemann K; Salanti G; Richter T; Knudsen B; Vande Woude GF; Harbeck N
Int J Cancer; 2005 Feb; 113(4):678-82. PubMed ID: 15455388
[TBL] [Abstract][Full Text] [Related]
12. RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck.
Kleer CG; Teknos TN; Islam M; Marcus B; Lee JS; Pan Q; Merajver SD
Clin Cancer Res; 2006 Aug; 12(15):4485-90. PubMed ID: 16899593
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of expression of RhoC with invasiveness of breast cancer cells in vitro].
Yuan Z; Su J; You JF; Wang JL; Cui XL; Zheng J
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):898-903. PubMed ID: 18478927
[TBL] [Abstract][Full Text] [Related]
14. Loss of annexin A1 expression in breast cancer progression.
Cao Y; Li Y; Edelweiss M; Arun B; Rosen D; Resetkova E; Wu Y; Liu J; Sahin A; Albarracin CT
Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):530-4. PubMed ID: 18776816
[TBL] [Abstract][Full Text] [Related]
15. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo.
Pillé JY; Denoyelle C; Varet J; Bertrand JR; Soria J; Opolon P; Lu H; Pritchard LL; Vannier JP; Malvy C; Soria C; Li H
Mol Ther; 2005 Feb; 11(2):267-74. PubMed ID: 15668138
[TBL] [Abstract][Full Text] [Related]
16. RhoC is essential for the metastasis of gastric cancer.
Liu N; Zhang G; Bi F; Pan Y; Xue Y; Shi Y; Yao L; Zhao L; Zheng Y; Fan D
J Mol Med (Berl); 2007 Oct; 85(10):1149-56. PubMed ID: 17549441
[TBL] [Abstract][Full Text] [Related]
17. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin-c is a selective marker of breast cancer.
Mirza M; Shaughnessy E; Hurley JK; Vanpatten KA; Pestano GA; He B; Weber GF
Int J Cancer; 2008 Feb; 122(4):889-97. PubMed ID: 17960616
[TBL] [Abstract][Full Text] [Related]
19. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
20. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
